One of the large pharmaceutical companies which focuses on multiple myeloma related meds, Novartis, will showcase data from 140 abstracts on its current oncology products and investigational agents at the 47th Annual Meeting of the American Society of Clinical Oncology (ASCO).
I will be there to report on the progress of a number of different drugs, including Norartis’ panobinostat and Zometa. Here are some pre-conference details, provided by the company:
LBH589 (panobinostat) – An update of a Phase Ib study of oral panobinostat in combination with bortezomib in patients with relapsed or relapsed and refractory multiple myeloma (ASCO abstract #8075; June 6, 1:00 – 5:00 PM CDT) and a Phase III trial in progress of panobinostat plus bortezomib in relapsed/refractory multiple myeloma: PANORAMA-1, which is currently enrolling (ASCO abstract #TPS227; June 6, 8:00 AM – 12:00 PM CDT).
Zometa – Two new Myeloma IX analyses evaluate the impact of treatment initiation and duration, and baseline bone disease status, on the effect of Zometa versus clodronate on progression-free survival, overall survival and skeletal-related events when used with first-line chemotherapy in patients with newly diagnosed multiple myeloma (ASCO abstract #8011; June 5, 11:00 – 11:15 AM CDT; ASCO abstract #8010; June 5, 10:45 – 11:00 AM CDT), as well as Austrian Breast & Colorectal Cancer Study Group Trial 12 (ABCSG-12) long-term follow-up data examining the impact of adjuvant Zometa therapy on disease-free survival and overall survival in premenopausal women with endocrine-responsive early breast cancer based on patient and tumor characteristics (ASCO abstract #520; June 7, 8:00 AM – 12:30 PM CDT).
I’m anxious to get started. This trip may distract me enough to help me forget my ever-worsening peripheral neuropathy (PN). More about that later today.
Feel good and keep smiling! Pat